CIK 0001806952
- Non-accelerated filer
- Smaller reporting company
Lyell Immunopharma, Inc.
Sign in to watch- Ticker
- LYEL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 833006753
- Phone
- +1 650-695-0677
- Business address
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $49,999,983
- in 2 filings
- Open-market sales, last 90 days
- $215,781
- in 9 filings
Net +$49,784,202. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 41 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-09 | Lee Gary K. Chief Scientific Officer | Grant or award | +40,000 | 52,700 | ||
| 2024-02-09 | Lee Gary K. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2024-02-09 | Newton Charles W. Chief Financial Officer | Grant or award | +40,000 | 48,729 | ||
| 2024-02-09 | Newton Charles W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +400,000 | 400,000 | ||
| 2024-02-09 | Seely Lynn President and CEO | Grant or award | +200,000 | 200,000 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +3,612,000 | 3,612,000 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −3,612,000 | 0 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +190,000 | 190,000 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −190,000 | 0 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +516,000 | 516,000 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −516,000 | 0 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Grant or award · Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2023-11-16 | Newton Charles W. Chief Financial Officer | Returned to the company · Stock Option (right to buy) | −500,000 | 0 | ||
| 2023-11-16 | Lee Gary K. Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +800,000 | 800,000 | ||
| 2023-11-16 | Lee Gary K. Chief Scientific Officer | Returned to the company · Stock Option (right to buy) | −800,000 | 0 | ||
| 2023-11-16 | Seely Lynn President and CEO | Grant or award · Stock Option (right to buy) | +7,500,000 | 7,500,000 | ||
| 2023-11-16 | Seely Lynn President and CEO | Returned to the company · Stock Option (right to buy) | −7,500,000 | 0 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Stock Option (right to buy) | +500,000 | 500,000 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Returned to the company · Stock Option (right to buy) | −500,000 | 0 | ||
| 2023-11-16 | Hill Stephen J. Chief Technical Ops. Officer | Grant or award · Stock Option (right to buy) | +165,000 | 165,000 |
Page 7 of 8 · 156 trades